ClinicalTrials.gg

Program

pelacarsen

Also written as “Pelacarsen”, “ISIS 681257” and “Pelacarsen (TQJ230)”.

Its studies are mostly in Cardiovascular Diseases · Atherosclerosis · Hyperlipoproteinemias · Acute Coronary Syndrome · Aortic Valve Stenosis, led by 2 companies.

Furthest: phase 3, since Jul 16, 201916 company-led studies, 4 open or runningNext primary completion: Feb 3, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis104 open or runningphase 3since Jul 16, 2019Jul 16, 2019Feb 3, 2028phase 3 · NCT06813911
Ionis Pharmaceuticals60 open or runningphase 2since Jan 31, 2017Apr 1, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Apr 1, 2015.

  1. Jul 16, 2019Novartis's first study: phase 3 study in Cardiovascular DiseasesNew to NovartisNovartis · NCT04023552 · 8,323 enrolled · United States, Argentina, Australia and more
  2. Aug 4, 2021Phase 1 study in Hepatic ImpairmentNovartis · NCT05026996 · 17 enrolled · United States
  3. Mar 14, 2022Phase 3 study in Cardiovascular DiseasesNovartis · NCT05305664 · 51 enrolled · Germany
  4. Apr 13, 2022Phase 1 study in Healthy ParticipantsIonis Pharmaceuticals · NCT05337878 · 29 enrolled · United States
  5. Dec 2, 2022Phase 2 study in Aortic Valve StenosisNovartis · NCT05646381 · 502 planned · United States, Austria, Belgium and more
  6. Jun 2, 2023Phase 3 study in HyperlipoproteinemiasNovartis · NCT05900141 · 41 enrolled · Germany
  7. Feb 12, 2024Phase 3 study in Cardiovascular DiseasesNovartis · NCT06267560 · 422 enrolled · United States, Puerto Rico
  8. Feb 3, 2025Phase 3 study in AtherosclerosisNovartis · NCT06813911 · 246 enrolled · United States, China, France and more
  9. Mar 12, 2025Phase 3 study in AtherosclerosisNovartis · NCT06875973 · 599 enrolled · United States, Puerto Rico
  10. Apr 1, 2026Phase 3 study in Cardiovascular DiseasesNovartis · NCT07517263 · 5,700 enrolled · United States, Argentina, Australia and more
  11. May 27, 2026Phase 3 study in Acute Coronary SyndromeNovartis · NCT07625306
  12. Oct 14, 2026Phase 3 study withdrawnStudy stoppedNCT07625306 · “Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”
  13. Oct 14, 2026Primary completion moved from 2028-12-07 to 2029-01-22Date moved laterphase 3 · +2 months · NCT07625306
  14. Nov 10, 2026Phase 3 study terminatedStudy stoppedNCT05900141 · “Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”

Ahead

  1. Feb 3, 2028Primary completion: phase 3 study in AtherosclerosisNovartis · NCT06813911
  2. Jan 9, 2030Primary completion: phase 3 study in Cardiovascular DiseasesNovartis · NCT07517263
  3. Mar 12, 2030Primary completion: phase 2 study in Aortic Valve StenosisNovartis · NCT05646381
  4. Dec 8, 2030Primary completion: phase 3 study in AtherosclerosisNovartis · NCT06875973

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07625306Acute Coronary Syndrome3WithdrawnNovartisJan 22, 20290
NCT07517263Cardiovascular Diseases · United States, Argentina, Australia and more3Active, not recruitingNovartisJan 9, 20305,700
NCT06875973Atherosclerosis · United States, Puerto Rico3Active, not recruitingNovartisDec 8, 2030599
NCT06813911Atherosclerosis · United States, China, France and more3Active, not recruitingNovartisFeb 3, 2028246
NCT06267560Cardiovascular Diseases · United States, Puerto Rico3CompletedNovartisMar 25, 2026422
NCT05900141Hyperlipoproteinemias · Germany3TerminatedNovartisOct 15, 202641
NCT05646381Aortic Valve Stenosis · United States, Austria, Belgium and more2RecruitingNovartisMar 12, 2030502
NCT05337878Healthy Participants · United States1CompletedIonis PharmaceuticalsDec 18, 201929
NCT05305664Cardiovascular Diseases · Germany3CompletedNovartisJan 28, 202551
NCT05026996Hepatic Impairment · United States1CompletedNovartisOct 19, 202217
NCT04023552Cardiovascular Diseases · United States, Argentina, Australia and more3CompletedNovartisJul 16, 20268,323
NCT03506854Renal Insufficiency · United States, Canada1CompletedIonis PharmaceuticalsOct 11, 201816
NCT03426033Cardiovascular Diseases · Canada1CompletedIonis PharmaceuticalsFeb 25, 201818
NCT03392051Cardiovascular Diseases · Canada1CompletedIonis PharmaceuticalsMar 18, 201818
NCT03070782Cardiovascular Diseases · United States, Canada, Denmark and more2CompletedIonis PharmaceuticalsJul 26, 2018286
NCT02414594Elevated Lipoprotein(a) · Canada1CompletedIonis PharmaceuticalsFeb 201660

How it is read

Names in the registry

  • “Pelacarsen”, 5 entries
  • “ISIS 681257”, 4 entries
  • “Pelacarsen (TQJ230)”, 2 entries
  • “TQJ230”, 2 entries
  • “Pelacarsen (TQJ230) 80 mg s.c.”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.